Literature DB >> 973982

Distribution and removal of human serum albumin-technetium 99m instilled intranasally.

F Y Aoki, J C Crowley.   

Abstract

The efficacy of antiviral drugs and vaccines administered intranasally may depend upon the technique of application. The distribution and time-course of removal of human serum albumin-technetium 99m (HSA-Tc 99m)-instilled intranasally were studied in eleven healthy volunteers using a gamma camera and an anterior sodium iodide scintillation detector. In 100 randomized studies material was delivered as drops in the supine position or as a spray to seated subjects. A significantly higher proportion of 'good' distributions (62 in 73 tests) was obtained with drops compared with spray (1 in 27). The volume administered was varied between 0.10 ml and 0.75 ml and the concentration of HSA was changed from 3 to 30% with no significant effect upon the distribution of time-course of removal; pertechnetate in isotonic saline was distributed and removed in a manner comparable to HSA-Tc 99m. Activity recorded by the detector showed an initial rapid fall associated with removal of most of the material from the nasal cavity, followed by a slower decline associated with the removal of material mainly from the anterior region of the nose. A multidose study confirmed that frequent administration by drops is required to maintain a high level of activity in the nasal cavity. Using this technique it should be possible to correlate measurements of antiviral efficacy and vaccines take-rates with certain characteristics of intranasal applicators; such studies may lead to the design of better devices.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 973982      PMCID: PMC1428928          DOI: 10.1111/j.1365-2125.1976.tb00640.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  5 in total

1.  CLEARANCE OF PARTICLES FROM THE HUMAN NOSE. PRELIMINARY REPORT.

Authors:  D F PROCTOR; H N WAGNER
Journal:  Arch Environ Health       Date:  1965-09

2.  Human nasal mucosal function in a controlled climate.

Authors:  I Andersen; G R Lundqvist; D F Proctor
Journal:  Arch Environ Health       Date:  1971-12

Review 3.  Airborne disease and the upper respiratory tract.

Authors:  D F Proctor
Journal:  Bacteriol Rev       Date:  1966-09

4.  A rapid and efficient method of preparing 99mTc-human serum albumin: its clinical applications.

Authors:  P P Benjamin
Journal:  Int J Appl Radiat Isot       Date:  1969-03

5.  Measurement of mucociliary function in man.

Authors:  M F Quinlan; S D Salman; D L Swift; H N Wagner; D F Proctor
Journal:  Am Rev Respir Dis       Date:  1969-01
  5 in total
  16 in total

1.  Comparison of nasal deposition and clearance of aerosol generated by nebulizer and an aqueous spray pump.

Authors:  J D Suman; B L Laube; R Dalby
Journal:  Pharm Res       Date:  1999-10       Impact factor: 4.200

2.  Antiviral activity of intranasally applied human leukocyte interferon.

Authors:  S B Greenberg; M W Harmon; P E Johnson; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

Review 3.  The nasal mucociliary clearance: relevance to nasal drug delivery.

Authors:  N G Schipper; J C Verhoef; F W Merkus
Journal:  Pharm Res       Date:  1991-07       Impact factor: 4.200

4.  The administration of drugs and vaccines by the intranasal route.

Authors:  D S Freestone; A L Weinberg
Journal:  Br J Clin Pharmacol       Date:  1976-10       Impact factor: 4.335

5.  Topical antibiotic therapy of chronic rhinosinusitis.

Authors:  Richard H Comstock; Kent Lam; Suzette Mikula
Journal:  Curr Infect Dis Rep       Date:  2010-03       Impact factor: 3.725

Review 6.  Interferon: therapeutic fact or fiction for the '80s?

Authors:  G M Scott; D A Tyrrell
Journal:  Br Med J       Date:  1980-06-28

7.  Failure of human fibroblast interferon to protect against rhinovirus infection.

Authors:  G M Scott; S Reed; T Cartwright; D Tyrrell
Journal:  Arch Virol       Date:  1980       Impact factor: 2.574

8.  Purified interferon as protection against rhinovirus infection.

Authors:  G M Scott; R J Phillpotts; J Wallace; D S Secher; K Cantell; D A Tyrrell
Journal:  Br Med J (Clin Res Ed)       Date:  1982-06-19

9.  Therapeutic activity of enviroxime against rhinovirus infection in volunteers.

Authors:  R J Phillpotts; J Wallace; D A Tyrrell; V B Tagart
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

10.  Human nasal epithelial cell culture system: evaluation of response to human interferons.

Authors:  M W Harmon; S B Greenberg; P E Johnson; R B Couch
Journal:  Infect Immun       Date:  1977-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.